- Home
- RIGL vs IIM Comparison
RIGL vs IIM Comparison
Compare RIGL & IIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- IIM
- Stock Information
- Founded
- RIGL 1996
- IIM 1993
- Country
- RIGL United States
- IIM United States
- Employees
- RIGL N/A
- IIM N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- IIM Investment Managers
- Sector
- RIGL Health Care
- IIM Finance
- Exchange
- RIGL Nasdaq
- IIM Nasdaq
- Market Cap
- RIGL 537.6M
- IIM 588.4M
- IPO Year
- RIGL 2000
- IIM N/A
- Fundamental
- Price
- RIGL $29.48
- IIM $12.60
- Analyst Decision
- RIGL Buy
- IIM
- Analyst Count
- RIGL 5
- IIM 0
- Target Price
- RIGL $38.20
- IIM N/A
- AVG Volume (30 Days)
- RIGL 492.6K
- IIM 122.2K
- Earning Date
- RIGL 11-04-2025
- IIM 01-01-0001
- Dividend Yield
- RIGL N/A
- IIM 4.63%
- EPS Growth
- RIGL N/A
- IIM N/A
- EPS
- RIGL 5.43
- IIM 0.02
- Revenue
- RIGL $267,921,000.00
- IIM N/A
- Revenue This Year
- RIGL $59.93
- IIM N/A
- Revenue Next Year
- RIGL N/A
- IIM N/A
- P/E Ratio
- RIGL $5.44
- IIM $591.50
- Revenue Growth
- RIGL 105.62
- IIM N/A
- 52 Week Low
- RIGL $13.57
- IIM $9.94
- 52 Week High
- RIGL $43.72
- IIM $12.32
- Technical
- Relative Strength Index (RSI)
- RIGL 46.18
- IIM 56.36
- Support Level
- RIGL $29.30
- IIM $12.52
- Resistance Level
- RIGL $30.94
- IIM $12.63
- Average True Range (ATR)
- RIGL 1.26
- IIM 0.10
- MACD
- RIGL 0.38
- IIM -0.03
- Stochastic Oscillator
- RIGL 53.61
- IIM 50.00
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About IIM Invesco Value Municipal Income Trust
Invesco Value Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide common shareholders with current income that is exempt from federal income tax.